Drug intelligence / Profile preview

HE009

Development stage: Unknown
Lead developer: Nanchang Hongyi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HE009 is an orally administered small molecule antagonist of the sphingosine-1-phosphate receptor 1 (S1PR1). It is being developed by Nanchang Hongyi Pharmaceutical for potential therapeutic use. The drug's primary mechanism involves blocking S1PR1, a receptor involved in immune cell trafficking and vascular integrity, which may have applications in autoimmune or inflammatory diseases. As of the latest available data, HE009 has completed Phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult subjects[1][2].

Targets

EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on HE009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HE009.

Explore the full profile